Under big biotech's wing
On mission for innovation, Biogen Idec opens incubator
Like other major biotechnology companies, Biogen Idec Inc. has a cadre of talented scientists working feverishly to discover breakthrough drugs. Over the years, the Cambridge biotech has also made acquisitions, established a $105 million venture fund, and licensed promising technologies to build a pipeline of potential life-saving therapies. (Full article: 797 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
